Advanced Functional Materials,
Год журнала:
2024,
Номер
unknown
Опубликована: Ноя. 5, 2024
Abstract
Glioblastoma
(GBM)
is
a
highly
malignant
intracranial
tumor
with
limited
treatment
options.
Bispecific
T‐cell
engagers
(BiTEs)
are
being
explored
for
GBM
treatment,
but
their
success
hindered
by
inadequate
T
cell
infiltration
and
activation
due
to
the
acidic
immunosuppressive
microenvironment.
Photothermal
immunotherapy
lyses
tumors
activates
immune
responses,
complementing
BiTEs.
This
study
innovatively
employs
donor
engineering
strategy
develop
hemicyanine
dyes
(Hcys)
that
emit
from
near‐infrared
(NIR)
I
NIR
II.
The
Hcy
excellent
properties
encapsulated
in
an
amphiphilic
micelle,
forming
nano
assembly
lactate
oxidase
(PLH1100).
PLH1100
exhibits
spectral
absorption
at
980
nm,
photothermal
conversion
efficiency
of
58.7%,
capability
NIR‐II
imaging.
Besides
ablation,
regulates
lactic
acid
metabolism
immunogenic
death,
improving
microenvironment
promoting
activation.
Further
studies
demonstrate
effectively
kills
human
murine
cells,
inhibits
orthotopic
U87
growth
BALB/c‐nu
mice,
enhances
efficacy
Fn14‐targeted
BiTE
GL261
C57BL/6
achieving
synergistic
“1+1>2”
therapeutic
effect.
Collectively,
this
work
opens
new
pathway
using
Hcy‐based
molecules
combined
drugs
therapy,
significant
clinical
potential.
Materials Today Bio,
Год журнала:
2025,
Номер
30, С. 101443 - 101443
Опубликована: Янв. 5, 2025
Glioblastoma
(GBM)
is
the
most
prevalent
primary
malignant
brain
tumor,
characterized
by
a
high
mortality
rate
and
poor
prognosis.
The
blood-brain
barrier
(BBB)
blood-tumor
(BTB)
present
significant
obstacles
to
efficacy
of
tumor-targeted
pharmacotherapy,
thereby
impeding
therapeutic
potential
numerous
candidate
drugs.
Targeting
delivery
adequate
doses
drug
across
BBB
treat
GBM
has
become
prominent
research
area
in
recent
years.
This
emphasis
driven
exploration
evaluation
diverse
technologies
for
with
some
already
undergoing
clinical
trials.
review
provides
thorough
overview
advancements
challenges
targeted
treatment.
It
specifically
emphasizes
systemic
administration
strategies
assess
their
limitations
Furthermore,
this
highlights
promising
future
directions
development
intelligent
systems
aimed
at
overcoming
current
enhancing
against
GBM.
These
not
only
support
foundational
on
but
also
offer
methodological
approaches
applications.
Materials Today Bio,
Год журнала:
2025,
Номер
30, С. 101441 - 101441
Опубликована: Янв. 1, 2025
The
therapeutic
effect
of
immune
checkpoint
inhibitors
(ICIs)
in
triple-negative
breast
cancer
(TNBC)
is
unsatisfactory.
"cold"
microenvironment
caused
by
tumor-associated
fibroblasts
(TAFs)
has
an
adverse
on
the
antitumor
response.
Therefore,
this
study,
mixed
cell
membrane-coated
porous
magnetic
nanoparticles
(PMNPs)
were
constructed
to
deliver
salvianolic
acid
B
(SAB)
induce
response,
facilitating
transition
from
a
"hot"
tumor
and
ultimately
enhancing
efficacy
inhibitors.
PMNP-SAB,
which
based
coating
red
blood
membrane
TAF
(named
PMNP-SAB@RTM),
can
simultaneously
achieve
dual
effects
"immune
escape"
"homologous
targeting".
Under
influence
external
field
(MF),
SAB
be
targeted
concentrated
at
site.
released
tumors
effectively
inhibit
production
extracellular
matrix
(ECM)
TAFs,
promote
T-cell
infiltration,
responses.
Ultimately,
combination
PMNP-SAB@RTM
BMS-1
(PD-1/PD-L1
inhibitor
1)
inhibited
growth.
Finally,
study
presents
precise
effective
new
strategy
for
TNBC
immunotherapy
basis
differentiation
microenvironments.
As
natural
agonists
of
the
stimulator
interferon
genes
(STING),
cyclic
dinucleotides
(CDNs)
have
been
identified
as
promising
immunotherapies
that
trigger
a
potent
immune
response
against
tumors.
However,
low
stability,
rapid
clearance,
inadequate
cellular
uptake,
and
inefficient
cytosol
localization
heavily
hinder
therapeutic
efficacy
hydrophilic
negatively
charged
2′,
3′-cyclic-GMP-AMP
(cGAMP).
How
to
efficiently
deliver
cGAMP
into
endoplasmic
reticulum
(ER)
activate
STING
for
priming
remains
challenging.
Here,
we
report
pH-responsive
guanidinium-rich
nanoagonist
(nPGSA)
delivery
cGAMP.
Compared
with
free
cGAMP,
nPGSA
achieves
up
37.4-fold
enhancement
internalization.
The
pH-sensitive
guanidinium-functional
design
facilitates
quick
release
endosome
escape,
thus
enabling
precise
ER
targeting
33.9-fold
amplification
sensibilization.
Furthermore,
through
modulation
tumor-associated
macrophage
(TAM)
polarization,
elicits
antigen-specific
sustained
tumor
regression
in
melanoma-
neuroblastoma-bearing
mice.
Our
study
provides
strategy
it
offers
insights
function
modulating
microenvironment
cancer
immunotherapy.
Biomacromolecules,
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 11, 2024
Glioblastoma
multiforme
(GBM)
is
a
highly
malignant
brain
tumor
with
poor
prognosis
and
limited
treatment
options.
Drug
delivery
by
stimuli-responsive
nanocarriers
holds
great
promise
for
improving
the
modalities
of
GBM.
At
beginning
review,
we
highlighted
stimuli-active
polymeric
carrying
therapies
that
potentially
boost
anti-GBM
responses
employing
endogenous
(pH,
redox,
hypoxia,
enzyme)
or
exogenous
stimuli
(light,
ultrasonic,
magnetic,
temperature,
radiation)
as
triggers
controlled
drug
release
mainly
via
hydrophobic/hydrophilic
transition,
degradability,
ionizability,
etc.
Modifying
these
target
ligands
further
enhanced
their
capacity
to
traverse
blood-brain
barrier
(BBB)
preferentially
accumulate
in
glioma
cells.
These
unique
features
lead
more
effective
cancer
minimal
adverse
reactions
superior
therapeutic
outcomes.
Finally,
review
summarizes
existing
difficulties
future
prospects
treating
Overall,
this
offers
theoretical
guidelines
developing
intelligent
versatile
facilitate
precise
GBM
clinical
settings.
ACS Applied Materials & Interfaces,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 9, 2025
Neuroinflammation
is
a
key
risk
factor
for
cognitive
impairment,
and
microglia
are
the
main
drivers.
Metformin
has
been
shown
to
suppress
inflammation
reduce
microglial
activation,
protecting
neurons
from
damage.
However,
its
clinical
efficacy
limited
by
low
bioavailability
metabolic
challenges,
especially
in
terms
of
precise
delivery
specific
targets.
To
overcome
this
problem,
we
developed
biomimetic
nanoparticles
(MePN@BM)
enhance
targeted
metformin.
Through
homologous
targeting,
efficiency
drugs
inflammatory
site
Parkinson's
disease
was
enhanced
improve
therapeutic
effect.
The
results
showed
that
MePN@BM
effectively
delivers
metformin
brain,
promotes
autophagy,
restores
mitochondrial
membrane
potential,
reduces
oxidative
stress.
In
(PD)
mouse
model,
improved
motor
function,
repaired
dopaminergic
neurons,
cleared
α-synuclein
aggregates.
Notably,
transcriptome
analysis
revealed
enriched
inflammation-related
pathways,
immunofluorescence
PD
mice
treated
with
had
higher
levels
anti-inflammatory
factors
lower
pro-inflammatory
factors.
Therefore,
it
provides
promising
strategy
treatment
inflammation-mediated
dysfunction.
